At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 729 enrolled
Drug / intervention
Ingenol Mebutate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Ingenol Mebutate Gel in Field Treatment of Actinic Keratosis on Full Face, Balding Scalp or Approximately 250 cm2 on the Chest
In Brief
A Phase 3 clinical trial evaluating Ingenol Mebutate and Vehicle for Actinic Keratosis. Completed, enrolled 729 participants across 1 site.
Detailed Summary
The objective of the trial is to investigate efficacy and safety of ingenol mebutate gel for actinic keratosis applied to large treatment areas once daily for three consecutive days on face, scalp or chest.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsActinic Keratosis
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 2015
Enrollment StartApr 2015
Primary CompletionMar 2016
Study CompletionMar 2017
TodayJul 2026
First PostedFeb 11, 2015
Enrollment StartApr 1, 2015
Primary CompletionMar 1, 2016
Study CompletionMar 1, 2017
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 11.4 years ago
Interventions
Ingenol Mebutatedrug
Vehicleother
Vehicle gel